81
Participants
Start Date
October 13, 2004
Primary Completion Date
October 28, 2005
Study Completion Date
October 21, 2010
Cilengitide 500 mg
Subjects will receive 1-hour intravenous infusion of 500 mg cilengitide twice weekly on Day 1 and 4 of each week during every 4-week cycle, for a total of 8 infusions per cycle. Cycles were repeated without pause until progressive disease (PD), unacceptable adverse events (AEs), or withdrawal of consent.
Cilengitide 2000 mg
Subjects will receive 1-hour intravenous infusion of 2000 mg cilengitide twice weekly on Day 1 and 4 of each week during every 4-week cycle, for a total of 8 infusions per cycle. Cycles were repeated without pause until progressive disease (PD), unacceptable adverse events (AEs), or withdrawal of consent.
Memorial Sloan Kettering Cancer Center, New York
University of Virginia Health System, Charlottesville
Duke University Medical Center, Durham
Good Samaritan Hospital/Tri Health Hatton Center, Cincinnati
Indiana University Medical Center, Indianapolis
Henry Ford Health System, Detroit
Northwestern University, Chicago
Washington University, St Louis
Baylor University Medical Center at Dallas, Dallas
University of Texas MD Anderson Cancer Center, Houston
Denise Damek, Aurora
Barrow Neurological Institute, Phoenix
UCLA Medical Center, Los Angeles
University of Alabama at Birmingham, Birmingham
Massachusetts General Hospital, Boston
University of Massachusetts, Worcester
University of Vermont/Fletcher Allen Healthcare, Burlington
Lead Sponsor
EMD Serono
INDUSTRY